Company / Current Liabilities
NeoGenomics Laboratories, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$88.3M
FY2025
5-year range
$87.2M / $301.2M
FY2021-FY2025
Trend
-70.7%
vs FY2024
Sector context
#128 of 160
Health Care
What the data says
NeoGenomics Laboratories, Inc.'s current liabilities of $88M is lower than 80% of companies in the Health Care sector (FY2025). Improved from $96M to $88M over the past 2 years.
Based on SEC 10-K filings.
$88M in FY2025 with a 5-year CAGR of +3.8%.
Improved from $96M to $88M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -0.6%
- 5-Year CAGR
- +3.8%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 160This company $88.3M Sector average $4.5B
▼
-98.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.8%, indicating consistent growth.
- In FY2025, current liabilities decreased 70.7% year-over-year.
- Ranks #128 out of 160 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $88.3M | -70.7% |
| FY2024 | $301.2M | +212.8% |
| FY2023 | $96.3M | +7.1% |
| FY2022 | $89.9M | +3.1% |
| FY2021 | $87.2M | +19.2% |
| FY2020 | $73.2M | +14.5% |
| FY2019 | $63.9M | +4.9% |
| FY2018 | $60.9M | +67.1% |
| FY2017 | $36.5M | -4.3% |
| FY2016 | $38.1M | -4.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026